



\*RESPONSE UNDER 37 CFR 1.116-  
EXPEDITED PROCEDURE EXAMINING  
GROUP 1733\*

Docket No.: 192592US0NPP CONT

COMMISSIONER FOR PATENTS  
ALEXANDRIA, VIRGINIA 22313

**OBLON**  
**SPIVAK**  
**McCLELLAND**  
**MAIER**  
**&**  
**NEUSTADT**  
**P.C.**

ATTORNEYS AT LAW

RE: Application Serial No.: 09/580,874  
Applicants: Michel M. LADANG, et al.  
Filing Date: May 30, 2000  
For: PROCESS FOR PREPARING A CROSSLINKED  
POLYOLEFIN FOAM  
Group Art Unit: 1733  
Examiner: GOFF II, JOHN L.

SIR:

Attached hereto for filing are the following papers:

**Request for Reconsideration**

Our check in the amount of \$0.00 is attached covering any required fees. In the event any variance exists between the amount enclosed and the Patent Office charges for filing the above-noted documents, including any fees required under 37 C.F.R. 1.136 for any necessary Extension of Time to make the filing of the attached documents timely, please charge or credit the difference to our Deposit Account No. 15-0030. Further, if these papers are not considered timely filed, then a petition is hereby made under 37 C.F.R. 1.136 for the necessary extension of time. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,  
MAIER & NEUSTADT, P.C.

Norman F. Oblon

Daniel R. Evans, Ph.D.

Registration No. 55,868

Customer Number

**22850**

(703) 413-3000 (phone)  
(703) 413-2220 (fax)



Corres. and Mail  
**BOX AF**

IFW/61 1733  
\*RESPONSE UNDER 37 CFR 1.116-  
EXPEDITED PROCEDURE EXAMINING  
GROUP 1733\*

DOCKET NO: 192592US0NPP CONT

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

IN RE APPLICATION OF :  
MICHEL M. LADANG, ET AL. : EXAMINER: GOFF II, JOHN L.  
SERIAL NO: 09/580,874 :  
FILED: MAY 30, 2000 : GROUP ART UNIT: 1733  
FOR: PROCESS FOR PREPARING A :  
CROSSLINKED POLYOLEFIN FOAM :

REQUEST FOR RECONSIDERATION

COMMISSIONER FOR PATENTS  
ALEXANDRIA, VIRGINIA 22313

SIR:

In response to the Office Action dated May 24, 2004, please amend the above-identified application as follows:

**A complete listing of the claims** begins on page 2 of this paper.

**Remarks** begin on page 3 of this paper.